Selective 5-HT3 receptor antagonist with alpha-7 nicotinic acetylcholine receptor partial agonism
A serotonergic indolylcarboxylate ester developed at Sandoz as a chemotherapy-induced antiemetic, distinguished from other setrons by intrinsic partial agonist activity at the alpha-7 nicotinic acetylcholine receptor and downstream cognitive, anti-inflammatory, and analgesic activity.
Abstract
Tropisetron, the indol-3-carboxylate ester of tropine and the third selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist introduced for the management of chemotherapy-induced and postoperative nausea and vomiting, is a clinically marketed antiemetic in approximately 50 jurisdictions outside the United States and a research compound of escalating interest in cognition, central nervous system inflammation, fibromyalgia, and Alzheimer’s disease. Distinct from ondansetron and granisetron in pharmacology though not in marketed indication, tropisetron is a dual-mechanism agent: at the 5-HT3 ligand-gated cation channel it produces insurmountable, low-nanomolar antagonism with approximately 1000-fold selectivity over other monoamine receptors, while at the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor it acts as a potent partial agonist with low-micromolar functional activity in heterologous expression systems and in cortical and hippocampal neurons. The compound is well tolerated at registered doses; the principal short-term adverse events are dose-dependent constipation, headache, and transient hypertension, and rare clinically significant arrhythmia is captured in pooled postmarketing data and prescribing labels. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.